Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $119,522, and 6 are calls, for a total amount of $458,440.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $150.0 and $560.0 for Vertex Pharmaceuticals, spanning the last three months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $150.0 to $560.0 in the last 30 days.
Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VRTX | CALL | SWEEP | BEARISH | 04/19/24 | $430.00 | $186.6K | 368 | 61 |
| VRTX | CALL | SWEEP | BEARISH | 04/19/24 | $430.00 | $89.3K | 368 | 92 |
| VRTX | PUT | SWEEP | BULLISH | 01/16/26 | $560.00 | $79.9K | 53 | 16 |
| VRTX | CALL | SWEEP | BULLISH | 01/17/25 | $330.00 | $67.5K | 167 | 5 |
| VRTX | CALL | TRADE | BEARISH | 04/19/24 | $430.00 | $58.5K | 368 | 111 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
In light of the recent options history for Vertex Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Vertex Pharmaceuticals
- With a trading volume of 898,155, the price of VRTX is up by 0.11%, reaching $437.95.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 19 days from now.
What The Experts Say On Vertex Pharmaceuticals
2 market experts have recently issued ratings for this stock, with a consensus target price of $415.0.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $415.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $415.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
